Autoantibodies to domain 1 of beta 2 glycoprotein i determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome

Lupus

Volumn 25, Issue 8, 2016, Pages 911-916

  Mahler, M ^a   Albesa, R ^a   Zohoury, N ^a   Bertolaccini, M L ^c   Ateka Barrutia, O ^b   Rodriguez Garcia, J L ^b   Norman, G L ^a   Khamashta, M ^b  

^a INOVA DIAGNOSTICS INC   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

antiphospholipid syndrome; Autoantibodies; beta 2 glycoprotein I; Domain 1; thrombosis

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PRIORITY JOURNAL; THROMBOSIS; BLOOD; COMPLICATION; IMMUNOLOGY; LUMINESCENCE; PROCEDURES; RISK FACTOR;

ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CROSS-SECTIONAL STUDIES; HUMANS; IMMUNOGLOBULIN G; LUMINESCENT MEASUREMENTS; RISK FACTORS; THROMBOSIS;

EID: 84973358481     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316640366     Document Type: Article

References (30)

1. Meroni PL, Borghi MO, Raschi E, Tedesco F,. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7: 330-339.
2. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
3. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
4. Lockshin MD, Sammaritano LR, Schwartzman S,. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000; 43: 440-443.
5. Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, Sanna G, Ateka-Barrutia O, Khamashta MA,. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS'). Ann Rheum Dis 2012; 71: 242-244.
6. Sanmarco M,. Clinical significance of antiphosphatidylethanolamine antibodies in the so-called "seronegative antiphospholipid syndrome". Autoimmun Rev 2009; 9: 90-92.
7. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA,. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124.
8. Iverson GM, Reddel S, Victoria EJ, et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002; 169: 7097-7103.
9. Shoenfeld Y, Krause I, Kvapil F, et al. Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol 2003; 23: 377-383.
10. Iverson GM, Victoria EJ, Marquis DM,. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 1998; 95: 15542-15546.
11. Mahler M, Norman GL, Meroni PL, Khamashta M,. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012; 12: 313-317.
12. Mahler M, Radice A, Yang W, et al. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta 2012; 413: 719-726.
13. Mondejar R, Gonzalez-Rodriguez C, Toyos-Saenz de Miera FJ, et al. Role of antiphospholipid score and anti-beta2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin Chim Acta 2014; 431: 174-178.
14. Mahler M, Bentow C, Serra J, Fritzler MJ,. Detection of autoantibodies using chemiluminescence technologies. Immunopharmacol Immunotoxicol 2016; 38: 14-20.
15. de Laat B, de Groot PG,. Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep 2011; 13: 70-76.
16. Andreoli L, Nalli C, Motta M, et al. Anti-beta-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile? Ann Rheum Dis 2011; 70: 380-383.
17. Andreoli L, Chighizola CB, Nalli C, et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against beta2-glycoprotein I domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol 2015; 67: 2196-2204.
18. Iverson GM, Matsuura E, Victoria EJ, Cockerill KA, Linnik MD,. The orientation of beta2GPI on the plate is important for the binding of anti-beta2GPI autoantibodies by ELISA. J Autoimmun 2002; 18: 289-297.
19. de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7: 1767-1773.
20. Banzato A, Pozzi N, Frasson R, et al. Antibodies to Domain I of beta(2)-glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res 2011; 128: 583-586.
21. Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012; 64: 504-512.
22. Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A,. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost 2012; 38: 322-327.
23. Ruffatti A, Tonello M, Visentin MS, et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 2011; 50: 1684-1689.
24. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118: 4714-4718.
25. de Laat B, Derksen RH, Urbanus RT, de Groot PG,. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540-1545.
26. Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syndrome: antibodies to Domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015; 13: 782-787.
27. Cucnik S, Kveder T, Ulcova-Gallova Z, et al. The avidity of anti-beta2-glycoprotein I antibodies in patients with or without antiphospholipid syndrome: a collaborative study in the frame of the European forum on antiphospholipid antibodies. Lupus 2011; 20: 1166-1171.
28. Bozic B, Cucnik S, Kveder T, Rozman B,. Avidity of anti-beta-2-glycoprotein I antibodies. Autoimmun Rev 2005; 4: 303-308.
29. Bossuyt X,. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 2009; 8: 543-548.
30. Sciascia S, Bertolaccini ML, Roccatello D, Khamashta MA,. Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis 2013; 72: 426-429.